Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes - PubMed (original) (raw)
Practice Guideline
. 2009 Jan;32(1):193-203.
doi: 10.2337/dc08-9025. Epub 2008 Oct 22.
Affiliations
- PMID: 18945920
- PMCID: PMC2606813
- DOI: 10.2337/dc08-9025
Practice Guideline
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M Nathan et al. Diabetes Care. 2009 Jan.
Abstract
The consensus algorithm for the medical management of type 2 diabetes was published in August 2006 with the expectation that it would be updated, based on the availability of new interventions and new evidence to establish their clinical role. The authors continue to endorse the principles used to develop the algorithm and its major features. We are sensitive to the risks of changing the algorithm cavalierly or too frequently, without compelling new information. An update to the consensus algorithm published in January 2008 specifically addressed safety issues surrounding the thiazolidinediones. In this revision, we focus on the new classes of medications that now have more clinical data and experience.
Figures
Figure 1
Initiation and adjustment of insulin regimens. Insulin regimens should be designed taking lifestyle and meal schedule into account. The algorithm can only provide basic guidelines for initiation and adjustment of insulin. See reference 90 for more detailed instructions. aPremixed insulins not recommended during adjustment of doses; however, they can be used conveniently, usually before breakfast and/or dinner, if proportion of rapid- and intermediate-acting insulins is similar to the fixed proportions available. bg, blood glucose.
Figure 2
Algorithm for the metabolic management of type 2 diabetes; Reinforce lifestyle interventions at every visit and check A1C every 3 months until A1C is <7% and then at least every 6 months. The interventions should be changed if A1C is ≥7%. aSulfonylureas other than glybenclamide (glyburide) or chlorpropamide. bInsufficient clinical use to be confident regarding safety. See text box, entitled
titration of metformin
. See Fig. 1 for initiation and adjustment of insulin. CHF, congestive heart failure.
Comment in
- A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Schwartz SS. Schwartz SS. Curr Med Res Opin. 2013 Jul;29(7):793-9. doi: 10.1185/03007995.2013.798637. Epub 2013 May 10. Curr Med Res Opin. 2013. PMID: 23614630
Similar articles
- Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for the Study of Diabetes. Nathan DM, et al. Diabetologia. 2009 Jan;52(1):17-30. doi: 10.1007/s00125-008-1157-y. Epub 2008 Oct 22. Diabetologia. 2009. PMID: 18941734 - Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
Mannucci E, Monami M, Pala L, Cocca C, Cresci B, Bardini G, Masotti G, Marchionni N, Rotella CM. Mannucci E, et al. Diabetes Care. 2007 Jan;30(1):193-4. doi: 10.2337/dc06-2060. Diabetes Care. 2007. PMID: 17192373 No abstract available. - Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B; Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes. Nathan DM, et al. Diabetologia. 2006 Aug;49(8):1711-21. doi: 10.1007/s00125-006-0316-2. Diabetologia. 2006. PMID: 16802130 No abstract available.
Cited by
- Risk vs benefit in diabetes pharmacotherapy: a rational approach to choosing pharmacotherapy in type 2 diabetes.
Cox ME, Feinglos MN. Cox ME, et al. Curr Diab Rep. 2013 Jun;13(3):319-28. doi: 10.1007/s11892-013-0374-z. Curr Diab Rep. 2013. PMID: 23512666 Review. - Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone.
Leal I, Romio SA, Schuemie M, Oteri A, Sturkenboom M, Trifirò G. Leal I, et al. Br J Clin Pharmacol. 2013 Mar;75(3):861-8. doi: 10.1111/j.1365-2125.2012.04401.x. Br J Clin Pharmacol. 2013. PMID: 22845019 Free PMC article. - Diabetes Remission after Nonsurgical Intensive Lifestyle Intervention in Obese Patients with Type 2 Diabetes.
Mottalib A, Sakr M, Shehabeldin M, Hamdy O. Mottalib A, et al. J Diabetes Res. 2015;2015:468704. doi: 10.1155/2015/468704. Epub 2015 May 31. J Diabetes Res. 2015. PMID: 26114120 Free PMC article. Clinical Trial. - Incretin therapy--present and future.
Garber AJ. Garber AJ. Rev Diabet Stud. 2011 Fall;8(3):307-22. doi: 10.1900/RDS.2011.8.307. Epub 2011 Nov 10. Rev Diabet Stud. 2011. PMID: 22262069 Free PMC article. Review.
References
- American Diabetes Association: Standards of medical care in diabetes—2008 (Position Statement). Diabetes Care 31(Suppl. 1):S12–S54, 2008 - PubMed
- European Diabetes Policy Group: A desk-top guide to type 2 diabetes mellitus. Diabet Med 16:716–730, 1999 - PubMed
- National Institute for Clinical Excellence: Clinical guidelines for type 2 diabetes mellitus: management of blood glucose [article online], 2002. Available from http://www.nice.org.uk./Guidancet/CG66
- Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 329:978–986, 1993 - PubMed
- Reichard P, Nilsson B-Y, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304–309, 1993 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical